

3050 Spruce Street
Saint Louis, Missouri 63103 USA
Telephone 800-325-5832 • (314) 771-5765
Fax (314) 286-7828
email: techserv@sial.com
sigma-aldrich.com

# **ProductInformation**

#### CD30/Fc Chimera

Human, Recombinant Expressed in NSO cells

Product Number C 5862

## **Product Description**

Recombinant Human CD30/Fc Chimera is produced from a DNA sequence encoding the extracellular domain of the human CD30 protein (amino acids 1-379)<sup>1</sup> fused to the C-terminal Fc region of human IgG1 by a polypeptide linker. The chimeric protein is expressed in mouse myeloma NSO cells. Based on N-terminal sequencing, recombinant human CD30/Fc has Phe 19 at the amino-terminus. The reduced monomer has a calculated molecular mass of approximately 66 kDa. Due to glycosylation, the recombinant protein migrates as an approximately 100 -110 kDa protein in SDS-PAGE under reducing conditions.

CD30 is a type I transmembrane glycoprotein of the tumor necrosis factor (TNF) receptor superfamily. It was originally identified as a cell surface antigen of Hodgkin's and Reed-Sternberg cells using monoclonal antibody Ki-1. The ligand for CD30 is CD30L (CD153). The binding of CD30L to CD30 mediates pleiotropic effects including cell proliferation, activation, differentiation, and apoptotic cell death. CD30 has a critical role in the pathophysiology of Hodgkin's disease and other CD30<sup>+</sup> lymphomas. CD30 acts as a costimulatory molecule in thymic negative selection.<sup>2</sup>

In addition to its expression on Hodgkin's and Reed-Sternberg cells, CD30 is also found in some non-Hodgkin's lymphomas (including Burkitt's lymphomas), virus-infected T and B cells, and on normal T and B cells after activation. In T cells, CD30 expression is present on a subset of T cells that produce Th2-type cytokines and on CD4<sup>+</sup>/CD8<sup>+</sup> thymocytes that coexpress CD45RO and the IL-4 receptor.

#### Reagent

Recombinant Human CD30/Fc Chimera is supplied as approximately 100  $\mu$ g of protein lyophilized from a 0.2  $\mu$ m filtered solution in phosphate buffered saline.

## **Preparation Instructions**

Reconstitute the contents of the vial using sterile phosphate-buffered saline (PBS) containing at least 0.1% human serum albumin or bovine serum albumin. Prepare a stock solution of no less than 50  $\mu$ g/ml.

## Storage/Stability

Store at  $-20\,^{\circ}$  C. Upon reconstitution, the product may be stored at 2-8  $^{\circ}$ C for up to one month. For extended storage, freeze in working aliquots. Repeated freezing and thawing is not recommended. Do not store in a frost-free freezer.

## **Product Profile**

Recombinant Human CD30/Fc Chimera is measured by its ability to neutralize the bioactivity of recombinant human CD30 ligand on HDLM-2 cells, a Hodgkin's lymphoma cell line.

The ED $_{50}$  for this effect is typically 0.04-0.12  $\mu g/ml$  in the presence of 1  $\mu g/ml$  recombinant human.

The  $ED_{50}$  is defined as the effective concentration of cytokine that elicits a 50% increase in cell growth in a cell based bioassay.

Purity: > 95% as determined by SDS-PAGE, visualized by silver stain.

Endotoxin level is < 1.0 endotoxin units/µg cytokine as determined by the LAL (Limulus amebocyte lysate) method.

#### References

- 1. Durkop, H., et al., Molecular cloning and expression of a new member of the nerve growth factor receptor family is characteristic for Hodgkin's disease. Cell, 68, 421-427 (1992).
- Chiarle, R., et al., CD30 overexpression enhances negative selection in the thymus and mediates
- programmed cell death via a Bcl-2-sensitive pathway. J. Immunol., 163, 194-205 (1999).
- 3. Gruss, H.J., et al., CD30 ligand expression in nonmalignant and Hodgkin's disease-involved lymphoid tissues. Am. J. Pathol., 149, 469-481 (1996).

kaa 01/03